PMID- 38090386 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231213 IS - 2770-9183 (Electronic) IS - 2770-9191 (Print) IS - 2770-9183 (Linking) VI - 2 IP - 5 DP - 2023 Oct TI - Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis. PG - 346-375 LID - 10.1002/cai2.97 [doi] AB - BACKGROUND: The wide use of antibody-drug conjugates (ADCs) is transforming the cancer-treatment landscape. Understanding the treatment-related adverse events (AEs) of ADCs is crucial for their clinical application. We conducted a meta-analysis to analyze the profile and incidence of AEs related to ADC use in the treatment of solid tumors and hematological malignancies. METHODS: We searched the PubMed, Embase, and Cochrane Library databases for articles published from January 2001 to October 2022. The overall profile and incidence of all-grade and grade >/= 3 treatment-related AEs were the primary outcomes of the analysis. RESULTS: A total of 138 trials involving 15,473 patients were included in this study. The overall incidence of any-grade treatment-related AEs was 100.0% (95% confidence interval [CI]: 99.9%-100.0%; I (2) = 89%) and the incidence of grade >/= 3 treatment-related AEs was 6.2% (95% CI: 3.0%-12.4%; I(2) = 99%). CONCLUSIONS: This study provides a comprehensive overview of AEs related to ADCs used for cancer treatment. ADC use resulted in a high incidence of any-grade AEs but a low incidence of grade >/= 3 AEs. The AE profiles and incidence differed according to cancer type, ADC type, and ADC components. CI - (c) 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd on behalf of Tsinghua University Press. FAU - Li, Jinming AU - Li J AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Shen, Guoshuang AU - Shen G AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Liu, Zhen AU - Liu Z AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Liu, Yaobang AU - Liu Y AD - Department of Surgical Oncology General Hospital of Ningxia Medical University Yinchuan Ningxia Hui Autonomous Region China. FAU - Wang, Miaozhou AU - Wang M AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Zhao, Fuxing AU - Zhao F AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Ren, Dengfeng AU - Ren D AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Xie, Qiqi AU - Xie Q AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Li, Zitao AU - Li Z AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Liu, Zhilin AU - Liu Z AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Zhao, Yi AU - Zhao Y AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Ma, Fei AU - Ma F AUID- ORCID: 0000-0001-9432-1902 AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. FAU - Liu, Xinlan AU - Liu X AD - Department of Surgical Oncology General Hospital of Ningxia Medical University Yinchuan Ningxia Hui Autonomous Region China. FAU - Xu, Zhengbo AU - Xu Z AD - Qinghai University Xining Qinghai China. FAU - Zhao, Jiuda AU - Zhao J AUID- ORCID: 0000-0002-1266-8943 AD - Breast Disease Diagnosis and Treatment Center Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University Xining Qinghai China. AD - Qinghai Provincial Clinical Research Center for Cancer; Qinghai Provincial Institute of Cancer Research Xining Qinghai China. LA - eng PT - Journal Article DEP - 20231015 PL - England TA - Cancer Innov JT - Cancer innovation JID - 9918713888606676 PMC - PMC10686142 OTO - NOTNLM OT - adverse event OT - antibody-drug conjugate OT - cancer OT - clinical trial OT - meta-analysis COIS- Professor Fei Ma and Jiuda Zhao are the members of the Cancer Innovation Editorial Board. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. The remaining authors declare no conflict of interest. EDAT- 2023/12/13 18:42 MHDA- 2023/12/13 18:43 PMCR- 2023/10/15 CRDT- 2023/12/13 13:08 PHST- 2023/07/08 00:00 [received] PHST- 2023/09/06 00:00 [revised] PHST- 2023/09/11 00:00 [accepted] PHST- 2023/12/13 18:43 [medline] PHST- 2023/12/13 18:42 [pubmed] PHST- 2023/12/13 13:08 [entrez] PHST- 2023/10/15 00:00 [pmc-release] AID - CAI297 [pii] AID - 10.1002/cai2.97 [doi] PST - epublish SO - Cancer Innov. 2023 Oct 15;2(5):346-375. doi: 10.1002/cai2.97. eCollection 2023 Oct.